@hackiebackup's peptide claims need a fact-check

What did @hackiebackup actually say?

The creator responded to a video warning women off tesamorelin because it might spike IGF-1 and disrupt estrogen. Their rebuttal had two main moves: first, they questioned the original poster's suggested alternative (CJC-1295/ipamorelin), arguing it works through the same pathways and would raise IGF-1 just as much. Second, they argued that IGF-1 responses to growth hormone secretagogues are highly variable, and that the body's own regulatory systems, especially somatostatin, act as a brake to prevent extreme supraphysiologic levels. They concluded that while a relationship between IGF-1 and estrogen exists, it is not significant enough to cause widespread hormonal chaos in women using tesamorelin.

One notable contradiction: they called CJC/ipamorelin a bad alternative in their closing sentence, after having used that same point to undermine the original poster's recommendation. Credit where it is due, they caught that inconsistency themselves.

Does the science back this up?

Partially, yes, but the framing is looser than the evidence warrants. The IGF-1 variability point is well-documented. The somatostatin feedback argument is real physiology. The estrogen-IGF-1 relationship, however, is more clinically relevant than the creator implied, especially in certain populations.

Tesamorelin is an FDA-approved GHRH analog studied primarily in HIV-associated lipodystrophy. In clinical trials, it consistently raised IGF-1 levels, often into the upper normal or above-normal range. Falutz et al. (2010, New England Journal of Medicine) found IGF-1 increases of roughly 60 to 100 ng/mL in treated patients. That is not trivial. The creator is correct that individual responses vary, but "varies" does not mean "usually nothing happens."

On the IGF-1 and estrogen connection, research shows estrogen upregulates IGF-1 receptor sensitivity, and IGF-1 itself can stimulate aromatase activity. This bidirectional relationship has been studied in breast cancer risk contexts. Key et al. (2003, Lancet Oncology) identified elevated IGF-1 as an independent risk factor for premenopausal breast cancer. Calling the connection a non-issue for most women is an oversimplification.

What did they get wrong (or right)?

They got the core mechanism right and got the CJC/ipamorelin takedown right. Where they stumbled is in the risk minimization.

Correct: Somatostatin does limit pulsatile GH release. The body does resist fully supraphysiologic states from secretagogues alone, at least in healthy individuals. And yes, "not every woman" will have hormonal disruption, that is statistically accurate given the limited real-world data.

Misleading: Saying IGF-1 increases are not a "definitive guarantee" risks implying they are unlikely. In studies, tesamorelin reliably raises IGF-1. Variability exists in the magnitude, not really in the direction. The creator's examples of secretagogue users at IGF-1 of 150 without context, such as age, sex, dose, and baseline levels, are anecdotes, not evidence.

Also missing entirely: women with estrogen-sensitive conditions, such as ER-positive breast cancer history, PCOS with elevated IGF-1 at baseline, or those on estrogen therapy, face a meaningfully different risk profile. The creator did not acknowledge this at all. Blanket reassurance without stratification is where this video falls short.

What should you actually know?

If you are a woman considering tesamorelin or any growth hormone secretagogue, the question is not whether IGF-1 will skyrocket. It probably will not reach dangerous levels in most healthy people. The real question is whether your baseline IGF-1, your hormonal context, and your health history make even a moderate increase worth monitoring.

Tesamorelin is only FDA-approved for HIV-associated lipodystrophy. Its use in general wellness or body composition optimization is off-label. That does not automatically make it dangerous, but it does mean the long-term safety data in healthy women is thin. The creator speaks with confidence about outcomes that simply have not been studied well in this population.

• Get baseline IGF-1 and estradiol labs before starting any GH secretagogue.
• Women with personal or family history of hormone-sensitive cancers should have a direct conversation with a physician before use, not a TikTok comment section.
• CJC-1295 and ipamorelin do work through overlapping pathways, and the creator is right that framing them as a safe swap for tesamorelin is not well-supported.
• Somatostatin feedback is real, but it is not a guarantee of safety at any dose or in all individuals.